Scheduled Autologous PRP Guided Injection in the Maxillary Bony Defects

Effect of Scheduled Autologous Platelet-rich Plasma Guided Injection in the Healing Process of Critical-sized Maxillary Bony Defects After Surgical Excision of Non- Malignant Lesions: A Prospective Randomized Clinical Trial.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07108933

Enrollment

Registered

2025-08-07

Start date

2023-08-15

Completion date

2025-04-15

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bony Defect

Keywords

Platelet-rich plasma, scheduled injection, healing process

Brief summary

Scheduled autologous platelet-rich plasma guided injection is done in critical-sized maxillary bony defects after surgical excision of non- malignant lesions.

Detailed description

The study aims to detect the effect of scheduled autologous platelet-rich plasma- guided injection in the healing process of critical-sized maxillary bony defects after surgical removal of non-malignant lesions by using bone volumetric analysis and density measuring with cone beam computed tomography.

Interventions

BIOLOGICALAutologous platelet-rich plasma

Guided injection of PRP in bony cavities of maxilla after surgical excision of non-malignant tumors.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Masking description

No masking

Intervention model description

Randomized Clinical Trial (RCT)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Age: 18-65 years (adults within a specific age range). Diagnosis: Non-malignant maxillary bony defects (e.g., benign tumors or cysts). Health: Generally healthy participants who can tolerate surgery. Platelet Function: No platelet disorders or blood-related conditions. Willingness: Informed consent and ability to follow the protocol. No Use of Blood Thinners: No current use of anticoagulants like aspirin.

Exclusion criteria

* Age: Children (under 18) and elderly (over 75). Malignant Lesions: Participants with cancer or pre-cancerous conditions. Systemic Illness: Severe conditions (e.g., uncontrolled diabetes, autoimmune disorders). Platelet Disorders: Low platelet count or bleeding disorders (e.g., hemophilia). Infections: Active infections or inflammatory conditions (e.g., periodontal disease). Pregnancy: Women who are pregnant or breastfeeding. Recent Surgery/Trauma: Recent maxillary surgery or trauma. Uncontrolled Medications: Use of blood thinners, NSAIDs, or immunosuppressive drugs. Non-compliance: Unwillingness or inability to follow-up with the protocol. Substance Abuse: Active drug or alcohol abuse.

Design outcomes

Primary

Measure	Time frame	Description
Volume of the injected bony defect	after 3 months	the volume of the injected bony defect is measured by Cone beam computed tomography in millimeters cubic.

Secondary

Measure	Time frame	Description
Bone density at the injected site	after 3 months	the density of bone formed at the injected site is measured by Cone beam computed tomography in Hounsfield unit.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026